A1 As the world's second-largest healthcare market, China's high-level opening up is expected to boost the development of an innovation ecosystem. We will see more opportunities and possibilities in pharmaceutical innovation and collaboration.

Astellas remains confident in business prospects in China in 2022. We expect for more new measures that ensure a more transparent and favorable market environment for foreign companies, and promote comprehensive patient-centric health management that includes a multilayered medical security system.

A2 We are very optimistic about the high-quality development of China's healthcare industry based on the significant progress that the country has made in healthcare reforms to encourage and accelerate innovation in the past couple of years.

In China, we aim to be a partner to achieve the goal of Healthy China 2030. We have recently upgraded corporate structure and strategy in China to seize opportunities and realize results through successful execution, and turn innovative science into value for patients.

A3 According to Astellas' latest financial results (Q3/FY2021), Astellas China continued its strong growth momentum, achieving revenue of 50.3 billion yen ($440 million). And I believe the momentum will continue in 2022 and towards 2025 with our upgraded corporate structure and Corporate Strategy Plan 2021.

A4 In 2022, although the global situation is complicated with some uncertainties, our confidence in China remains unchanged as we have witnessed the strong resilience of the Chinese economy against the COVID-19 pandemic during the past two years.

We will continue to deepen our cooperation with existing Chinese local partners like what we did in the past, and partner with them to formulate a healthy healthcare ecosystem for sustainable and high-quality development of the industry.

A5 Our investment in China will continue since China has risen to the top tier of Astellas' global strategic markets based on its strong performance. In November 2021, we just made an investment in corporate structure upgrade in China, a new structure, for the purpose of achieving a synergistic effect for Astellas' long-term development in China.

Moving forward, we will continue to focus on addressing unmet medical needs, particularly in oncology and specialty medicines, channel our energies into providing faster and more efficient value for Chinese patients and work with our stakeholders in China, together contributing to the achievement of Healthy China 2030.